Detalles de la búsqueda
1.
Margetuximab in HER2-positive metastatic breast cancer.
Future Oncol
; 19(16): 1099-1112, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-37170847
2.
FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer.
Proc Natl Acad Sci U S A
; 116(52): 26823-26834, 2019 Dec 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-31826955
3.
Management of hormone receptor-positive, human epidermal growth factor 2-negative metastatic breast cancer.
Breast Cancer Res Treat
; 190(2): 189-201, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-34515904
4.
Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer.
Breast Cancer Res Treat
; 189(1): 187-202, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-34173924
5.
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial).
Breast Cancer Res Treat
; 189(1): 103-110, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-34120223
6.
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance.
Br J Cancer
; 120(3): 331-339, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30555156
7.
Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia.
Breast Cancer Res Treat
; 177(2): 427-435, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31218477
8.
Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis.
BMC Cancer
; 19(1): 220, 2019 Mar 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30871481
9.
FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer.
Proc Natl Acad Sci U S A
; 113(43): E6600-E6609, 2016 10 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-27791031
10.
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.
Breast Cancer Res Treat
; 167(3): 731-740, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29110152
11.
Targeting HER2 for the treatment of breast cancer.
Annu Rev Med
; 66: 111-28, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25587647
12.
Retrospective review of genomic testing in breast cancer: Does it improve outcome?
Breast Cancer Res Treat
; 163(1): 191-195, 2017 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-28224382
13.
Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer: The SCALP Randomized Clinical Trial.
JAMA
; 317(6): 596-605, 2017 02 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-28196254
14.
Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis.
Breast Cancer Res
; 17: 3, 2015 Jan 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-25572662
15.
A phase II trial of capecitabine concomitantly with whole-brain radiotherapy followed by capecitabine and sunitinib for brain metastases from breast cancer.
Oncologist
; 20(1): 13, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25378456
16.
Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial.
Lancet Oncol
; 15(2): 156-63, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24439313
17.
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
Breast Cancer Res
; 16(5): 430, 2014 Sep 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-25212826
18.
Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance.
Breast Cancer Res Treat
; 144(2): 263-72, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24554387
19.
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial.
JAMA Oncol
; 10(3): 362-371, 2024 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38236590
20.
Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2-Expressing Metastatic Breast Cancer.
JCO Oncol Pract
; 19(8): 539-546, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37207306